EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion

Experimental Cell Research

Volumn 292, Issue 2, 2004, Pages 295-303

  Smith, Loraine M ^a   Walsh, Patrick T ^a   Rüdiger, Thomas ^b   Cotter, Thomas G ^a   Mc Carthy, Tommie V ^a   Marx, Alexander ^b   O'Connor, Rosemary ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CD28; EphA3; IGF 1; Jurkats; T cells

Indexed keywords

BLOCKING ANTIBODY; CD28 ANTIGEN; EPHRIN; EPHRIN A5; EPHRIN RECEPTOR; FIBRONECTIN; SOMATOMEDIN BINDING PROTEIN 1;

ARTICLE; CELL ADHESION; CELL CULTURE; CELL MOTILITY; CELL STIMULATION; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; T LYMPHOCYTE; THYMOCYTE;

EID: 0347623123     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2003.08.021     Document Type: Article

References (47)

1. Thompson C.B., Lindsten T., Ledbetter J.A., Kunkel S.L., Young H.A., Emerson S.G., Leiden J.M., June C.H. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. U. S. A. 86:1989;1333.
2. Boise L.H., Minn A.J., Noel P.J., June C.H., Accavitti M.A., Lindsten T., Thompson C.B. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 3:1995;87.
3. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol. Today. 15:1994;321.
4. Hutchcroft J.E., Bierer B.E. Activation-dependent phosphorylation of the T-lymphocyte surface receptor CD28 and associated proteins. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3260.
5. Siefken R., Klein-Hessling S., Serfling E., Kurrle R., Schwinzer R. A CD28-associated signaling pathway leading to cytokine gene transcription and T cell proliferation without TCR engagement. J. Immunol. 161:1998;1645.
6. Yin D., Zhang L., Wang R., Radvanyi L., Haudenschild C., Fang Q., Kehry M.R., Shi Y. Ligation of CD28 in vivo induces CD40 ligand expression and promotes B cell survival. J. Immunol. 163:1999;4328.
7. Walsh P.T., O'Connor R. The insulin-like growth factor-I receptor is regulated by CD28 and protects activated T cells from apoptosis. Eur. J. Immunol. 30:2000;1010.
8. Diehn M., Alizadeh A.A., Rando O.J., Liu C.L., Stankunas K., Botstein D., Crabtree G.R., Brown P.O. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11796.
9. Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F., Macaulay V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62:2002;2942.
10. Adams T.E., Epa V.C., Garrett T.P., Ward C.W. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol. Life Sci. 57:2000;1050.
11. Venuprasad K., Parab P., Prasad D.V., Sharma S., Banerjee P.R., Deshpande M., Mitra D.K., Pal S., Bhadra R., Mitra D., Saha B. Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression. Eur. J. Immunol. 31:2001;1536.
12. Shapiro V.S., Mollenauer M.N., Weiss A. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. Blood. 98:2001;187.
13. Walsh P.T., Smith L.M., O'Connor R. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology. 107:2002;461.
14. Krause D., Lyons A., Fennelly C., O'Connor R. Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol. J. Biol. Chem. 276:2001;19244.
15. Nenninger R., Schultz A., Hoffacker V., Helmreich M., Wilisch A., Vandekerckhove B., Hunig T., Schalke B., Schneider C., Tzartos S., Kalbacher H., Muller-Hermelink H.K., Marx A. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab. Invest. 78:1998;743.
16. Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. 2001;IARC Press, Lyon.
17. Sternberger L.A. Immunochemistry. 1974;Prentice-Hall, Englewood Cliffs, NJ.
18. O'Connor R., Kauffmann-Zeh A., Liu Y., Lehar S., Evan G.I., Baserga R., Blattler W.A. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell Biol. 17:1997;427.
19. Boyd A.W., Ward L.D., Wicks I.P., Simpson R.J., Salvaris E., Wilks A., Welch K., Loudovaris M., Rockman S., Busmanis I. Isolation and characterization of a novel receptor-type protein tyrosine kinase (hek) from a human pre-B cell line. J. Biol. Chem. 267:1992;3262.
20. Chiari R., Hames G., Stroobant V., Texier C., Maillere B., Boon T., Coulie P.G. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 60:2000;4855.
21. Lackmann M., Mann R.J., Kravets L., Smith F.M., Bucci T.A., Maxwell K.F., Howlett G.J., Olsson J.E., Vanden Bos T., Cerretti D.P., Boyd A.W. Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor. J. Biol. Chem. 272:1997;16521.
22. Vergara-Silva A., Schaefer K.L., Berg L.J. Compartmentalized Eph receptor and Ephrin expression in the thymus. Gene Expr. Patterns. 2:2002;261.
23. Lawrenson I.D., Wimmer-Kleikamp S.H., Lock P., Schoenwaelder S.M., Down M., Boyd A.W., Alewood P.F., Lackmann M. Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J. Cell Sci. 115:2002;1059.
24. Davis S., Gale N.W., Aldrich T.H., Maisonpierre P.C., Lhotak V., Pawson T., Goldfarb M., Yancopoulos G.D. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science. 266:1994;816.
25. Rohlik Q.T., Adams D., Kull F.C. Jr., Jacobs S. An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem. Biophys. Res. Commun. 149:1987;276.
26. Gale N.W., Holland S.J., Valenzuela D.M., Flenniken A., Pan L., Ryan T.E., Henkemeyer M., Strebhardt K., Hirai H., Wilkinson D.G., Pawson T., Davis S., Yancopoulos G.D. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron. 17:1996;9.
27. Friedman G.C., O'Leary D.D. Eph receptor tyrosine kinases and their ligands in neural development. Curr. Opin. Neurobiol. 6:1996;127.
28. Pasquale E.B. The Eph family of receptors. Curr. Opin. Cell Biol. 9:1997;608.
29. Orioli D., Henkemeyer M., Lemke G., Klein R., Pawson T. Sek4 and Nuk receptors cooperate in guidance of commissural axons and in palate formation. EMBO J. 15:1996;6035.
30. Pandey A., Shao H., Marks R.M., Polverini P.J., Dixit V.M. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science. 268:1995;567.
31. Aasheim H.C., Terstappen L.W., Logtenberg T. Regulated expression of the Eph-related receptor tyrosine kinase Hek11 in early human B lymphopoiesis. Blood. 90:1997;3613.
32. Inada T., Iwama A., Sakano S., Ohno M., Sawada K., Suda T. Selective expression of the receptor tyrosine kinase, HTK, on human erythroid progenitor cells. Blood. 89:1997;2757.
33. Dottori M., Down M., Huttmann A., Fitzpatrick D.R., Boyd A.W. Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood. 94:1999;2477.
34. Maru Y., Hirai H., Takaku F. Overexpression confers an oncogenic potential upon the eph gene. Oncogene. 5:1990;445.
35. Wicks I.P., Wilkinson D., Salvaris E., Boyd A.W. Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines. Proc. Natl. Acad. Sci. U. S. A. 89:1992;1611.
36. Wicks I.P., Lapsys N.M., Baker E., Campbell L.J., Boyd A.W., Sutherland G.R. Localization of a human receptor tyrosine kinase (ETK1) to chromosome region 3p11.2. Genomics. 19:1994;38.
37. O'Connor R. Survival factors and apoptosis. Adv. Biochem. Eng. Biotechnol. 62:1998;137.
38. Valentinis B., Romano G., Peruzzi F., Morrione A., Prisco M., Soddu S., Cristofanelli B., Sacchi A., Baserga R. Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J. Biol. Chem. 274:1999;12423.
39. Zeigler M.E., Chi Y., Schmidt T., Varani J. Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J. Cell Physiol. 180:1999;271.
40. Zheng W.H., Kar S., Quirion R. Insulin-like growth factor-1-induced phosphorylation of the forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells. J. Biol. Chem. 275:2000;39152.
41. Hong F., Kwon S.J., Jhun B.S., Kim S.S., Ha J., Kim S.J., Sohn N.W., Kang C., Kang I. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci. 68:2001;1095.
42. Smith L.E., Shen W., Perruzzi C., Soker S., Kinose F., Xu X., Robinson G., Driver S., Bischoff J., Zhang B., Schaeffer J.M., Senger D.R. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med. 5:1999;1390.
43. Bagheri-Yarmand R., Kourbali Y., Mabilat C., Morere J.F., Martin A., Lu H., Soria C., Jozefonvicz J., Crepin M. The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br. J. Cancer. 78:1998;111.
44. Lhotak V., Pawson T. Biological and biochemical activities of a chimeric epidermal growth factor-Elk receptor tyrosine kinase. Mol. Cell Biol. 13:1993;7071.
45. Brambilla R., Schnapp A., Casagranda F., Labrador J.P., Bergemann A.D., Flanagan J.G., Pasquale E.B., Klein R. Membrane-bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases. EMBO J. 14:1995;3116.
46. Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D., Van Etten R.L., Daniel T.O. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 12:1998;667.
47. Sharfe N., Freywald A., Toro A., Dadi H., Roifman C. Ephrin stimulation modulates T cell chemotaxis. Eur. J. Immunol. 32:2002;3745.